Drug Profile
Anti-CD19 CAR T cell therapeutic - Beijing Doing Biomedical
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Beijing Doing Biomedical
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in China (Parenteral, Infusion)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in China (Parenteral, Infusion)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in China (Parenteral, Infusion)